APO Research
Talk to an analyst

APO RESEARCH · REPORT

CGT Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global CGT Drugs Market Outlook and Growth Opportunities 2026

30 December 2025192 pages

Choose your research edition.

Industry ResearchCGT Drugs Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal CGT Drugs Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal CGT Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CGT Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal CGT Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global CGT Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for CGT Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CGT Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CGT Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the CGT Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the CGT Drugs market include Bluebird Bio, Celgene Corporation, Juno Therapeutics, Kite Pharma, Orchard Therapeutics, Spark Therapeutics, Amgen, Fosun Kite Biotechnology and GSK, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global CGT Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CGT Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CGT Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the CGT Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

CGT Drugs Segment by Company

Bluebird Bio

Celgene Corporation

Juno Therapeutics

Kite Pharma

Orchard Therapeutics

Spark Therapeutics

Amgen

Fosun Kite Biotechnology

GSK

Novartis

SiBiono

Sunway Biotech

Janssen Biotech

Sequoia

CGT Drugs Segment by Type

CAR-T Therapy

Viral Vector Therapy

Stem Cell Therapy

Oncolytic Virus Therapy

CGT Drugs Segment by Application

Tumor Disease

Eye Disease

Rare Disease

Others

CGT Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global CGT Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions CGT Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify CGT Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze CGT Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CGT Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CGT Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CGT Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the CGT Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CGT Drugs industry.

Chapter 3: Detailed analysis of CGT Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of CGT Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of CGT Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. CGT Drugs Industry Trends Table 2. CGT Drugs Industry Drivers Table 3. CGT Drugs Industry Opportunities and Challenges Table 4. CGT Drugs Industry Restraints Table 5. Global CGT Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global CGT Drugs Revenue Share by Company (2021-2026) Table 7. Global CGT Drugs Sales Volume by Company (Tons) & (2021-2026) Table 8. Global CGT Drugs Sales Volume Share by Company (2021-2026) Table 9. Global CGT Drugs Average Price (US$/Ton) of Company (2021-2026) Table 10. Global CGT Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global CGT Drugs Key Company Manufacturing Base & Headquarters Table 12. Global CGT Drugs Company, Product Type & Application Table 13. Global CGT Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global CGT Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of CAR-T Therapy Table 18. Significant Companies of Viral Vector Therapy Table 19. Significant Companies of Stem Cell Therapy Table 20. Significant Companies of Oncolytic Virus Therapy Table 21. Global CGT Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 22. Global CGT Drugs Sales Volume by Type (2021-2026) & (Tons) Table 23. Global CGT Drugs Sales Volume by Type (2027-2032) & (Tons) Table 24. Global CGT Drugs Sales Volume Share by Type (2021-2026) Table 25. Global CGT Drugs Sales Volume Share by Type (2027-2032) Table 26. Global CGT Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global CGT Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global CGT Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global CGT Drugs Sales Value Share by Type (2021-2026) Table 30. Global CGT Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Tumor Disease Table 32. Significant Companies of Eye Disease Table 33. Significant Companies of Rare Disease Table 34. Significant Companies of Others Table 35. Global CGT Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 36. Global CGT Drugs Sales Volume by Application (2021-2026) & (Tons) Table 37. Global CGT Drugs Sales Volume by Application (2027-2032) & (Tons) Table 38. Global CGT Drugs Sales Volume Share by Application (2021-2026) Table 39. Global CGT Drugs Sales Volume Share by Application (2027-2032) Table 40. Global CGT Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global CGT Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global CGT Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global CGT Drugs Sales Value Share by Application (2021-2026) Table 44. Global CGT Drugs Sales Value Share by Application (2027-2032) Table 45. Global CGT Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 46. Global CGT Drugs Sales by Region (2021-2026) & (Tons) Table 47. Global CGT Drugs Sales Market Share by Region (2021-2026) Table 48. Global CGT Drugs Sales by Region (2027-2032) & (Tons) Table 49. Global CGT Drugs Sales Market Share by Region (2027-2032) Table 50. Global CGT Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global CGT Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global CGT Drugs Sales Value Share by Region (2021-2026) Table 53. Global CGT Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global CGT Drugs Sales Value Share by Region (2027-2032) Table 55. Global CGT Drugs Market Average Price (US$/Ton) by Region (2021-2026) Table 56. Global CGT Drugs Market Average Price (US$/Ton) by Region (2027-2032) Table 57. Global CGT Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 58. Global CGT Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global CGT Drugs Sales by Country (2021-2026) & (Tons) Table 60. Global CGT Drugs Sales Market Share by Country (2021-2026) Table 61. Global CGT Drugs Sales by Country (2027-2032) & (Tons) Table 62. Global CGT Drugs Sales Market Share by Country (2027-2032) Table 63. Global CGT Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global CGT Drugs Sales Value Market Share by Country (2021-2026) Table 65. Global CGT Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global CGT Drugs Sales Value Market Share by Country (2027-2032) Table 67. Bluebird Bio Company Information Table 68. Bluebird Bio Business Overview Table 69. Bluebird Bio CGT Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 70. Bluebird Bio CGT Drugs Product Portfolio Table 71. Bluebird Bio Recent Development Table 72. Celgene Corporation Company Information Table 73. Celgene Corporation Business Overview Table 74. Celgene Corporation CGT Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 75. Celgene Corporation CGT Drugs Product Portfolio Table 76. Celgene Corporation Recent Development Table 77. Juno Therapeutics Company Information Table 78. Juno Therapeutics Business Overview Table 79. Juno Therapeutics CGT Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 80. Juno Therapeutics CGT Drugs Product Portfolio Table 81. Juno Therapeutics Recent Development Table 82. Kite Pharma Company Information Table 83. Kite Pharma Business Overview Table 84. Kite Pharma CGT Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 85. Kite Pharma CGT Drugs Product Portfolio Table 86. Kite Pharma Recent Development Table 87. Orchard Therapeutics Company Information Table 88. Orchard Therapeutics Business Overview Table 89. Orchard Therapeutics CGT Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 90. Orchard Therapeutics CGT Drugs Product Portfolio Table 91. Orchard Therapeutics Recent Development Table 92. Spark Therapeutics Company Information Table 93. Spark Therapeutics Business Overview Table 94. Spark Therapeutics CGT Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 95. Spark Therapeutics CGT Drugs Product Portfolio Table 96. Spark Therapeutics Recent Development Table 97. Amgen Company Information Table 98. Amgen Business Overview Table 99. Amgen CGT Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 100. Amgen CGT Drugs Product Portfolio Table 101. Amgen Recent Development Table 102. Fosun Kite Biotechnology Company Information Table 103. Fosun Kite Biotechnology Business Overview Table 104. Fosun Kite Biotechnology CGT Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 105. Fosun Kite Biotechnology CGT Drugs Product Portfolio Table 106. Fosun Kite Biotechnology Recent Development Table 107. GSK Company Information Table 108. GSK Business Overview Table 109. GSK CGT Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 110. GSK CGT Drugs Product Portfolio Table 111. GSK Recent Development Table 112. Novartis Company Information Table 113. Novartis Business Overview Table 114. Novartis CGT Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 115. Novartis CGT Drugs Product Portfolio Table 116. Novartis Recent Development Table 117. SiBiono Company Information Table 118. SiBiono Business Overview Table 119. SiBiono CGT Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 120. SiBiono CGT Drugs Product Portfolio Table 121. SiBiono Recent Development Table 122. Sunway Biotech Company Information Table 123. Sunway Biotech Business Overview Table 124. Sunway Biotech CGT Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 125. Sunway Biotech CGT Drugs Product Portfolio Table 126. Sunway Biotech Recent Development Table 127. Janssen Biotech Company Information Table 128. Janssen Biotech Business Overview Table 129. Janssen Biotech CGT Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 130. Janssen Biotech CGT Drugs Product Portfolio Table 131. Janssen Biotech Recent Development Table 132. Sequoia Company Information Table 133. Sequoia Business Overview Table 134. Sequoia CGT Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 135. Sequoia CGT Drugs Product Portfolio Table 136. Sequoia Recent Development Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. CGT Drugs Distributors List Table 140. CGT Drugs Customers List Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. CGT Drugs Product Image Figure 2. Global CGT Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CGT Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global CGT Drugs Sales (2021-2032) & (Tons) Figure 5. Global CGT Drugs Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global CGT Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. CAR-T Therapy Image Figure 10. Viral Vector Therapy Image Figure 11. Stem Cell Therapy Image Figure 12. Oncolytic Virus Therapy Image Figure 13. Global CGT Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 14. Global CGT Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global CGT Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global CGT Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global CGT Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global CGT Drugs Sales Value Share by Type (2021-2032) Figure 19. Tumor Disease Image Figure 20. Eye Disease Image Figure 21. Rare Disease Image Figure 22. Others Image Figure 23. Global CGT Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 24. Global CGT Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global CGT Drugs Sales Volume Share by Application (2021-2032) Figure 26. Global CGT Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global CGT Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global CGT Drugs Sales Value Share by Application (2021-2032) Figure 29. Global CGT Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 30. Global CGT Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global CGT Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global CGT Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America CGT Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. North America CGT Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe CGT Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Europe CGT Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific CGT Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific CGT Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America CGT Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. South America CGT Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa CGT Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa CGT Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt CGT Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt CGT Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt CGT Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. CGT Drugs Value Chain Figure 128. Manufacturing Cost Structure Figure 129. CGT Drugs Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • CAR-T Therapy
  • Viral Vector Therapy
  • Stem Cell Therapy
  • Oncolytic Virus Therapy
Applications
  • Tumor Disease
  • Eye Disease
  • Rare Disease
  • Others
Companies covered
  • Bluebird Bio
  • Celgene Corporation
  • Juno Therapeutics
  • Kite Pharma
  • Orchard Therapeutics
  • Spark Therapeutics
  • Amgen
  • Fosun Kite Biotechnology
  • GSK
  • Novartis
  • SiBiono
  • Sunway Biotech
  • Janssen Biotech
  • Sequoia

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global CGT Drugs Sales Value (2021-2032)
  4. 1.2.2 Global CGT Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global CGT Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 CGT Drugs Market Dynamics
  1. 2.1 CGT Drugs Industry Trends
  2. 2.2 CGT Drugs Industry Drivers
  3. 2.3 CGT Drugs Industry Opportunities and Challenges
  4. 2.4 CGT Drugs Industry Restraints
3 CGT Drugs Market by Company
  1. 3.1 Global CGT Drugs Company Revenue Ranking in 2025
  2. 3.2 Global CGT Drugs Revenue by Company (2021-2026)
  3. 3.3 Global CGT Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global CGT Drugs Average Price by Company (2021-2026)
  5. 3.5 Global CGT Drugs Company Ranking (2024-2026)
  6. 3.6 Global CGT Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global CGT Drugs Company Product Type and Application
  8. 3.8 Global CGT Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global CGT Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 CGT Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 CGT Drugs Market by Type
  1. 4.1 CGT Drugs Type Introduction
  2. 4.1.1 CAR-T Therapy
  3. 4.1.2 Viral Vector Therapy
  4. 4.1.3 Stem Cell Therapy
  5. 4.1.4 Oncolytic Virus Therapy
  6. 4.2 Global CGT Drugs Sales Volume by Type
  7. 4.2.1 Global CGT Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global CGT Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global CGT Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global CGT Drugs Sales Value by Type
  11. 4.3.1 Global CGT Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global CGT Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global CGT Drugs Sales Value Share by Type (2021-2032)
5 CGT Drugs Market by Application
  1. 5.1 CGT Drugs Application Introduction
  2. 5.1.1 Tumor Disease
  3. 5.1.2 Eye Disease
  4. 5.1.3 Rare Disease
  5. 5.1.4 Others
  6. 5.2 Global CGT Drugs Sales Volume by Application
  7. 5.2.1 Global CGT Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global CGT Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global CGT Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global CGT Drugs Sales Value by Application
  11. 5.3.1 Global CGT Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global CGT Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global CGT Drugs Sales Value Share by Application (2021-2032)
6 CGT Drugs Regional Sales and Value Analysis
  1. 6.1 Global CGT Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CGT Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global CGT Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global CGT Drugs Sales by Region (2027-2032)
  5. 6.3 Global CGT Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global CGT Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global CGT Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global CGT Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global CGT Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America CGT Drugs Sales Value (2021-2032)
  12. 6.6.2 North America CGT Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe CGT Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe CGT Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific CGT Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific CGT Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America CGT Drugs Sales Value (2021-2032)
  21. 6.9.2 South America CGT Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa CGT Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa CGT Drugs Sales Value Share by Country, 2025 VS 2032
7 CGT Drugs Country-level Sales and Value Analysis
  1. 7.1 Global CGT Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global CGT Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global CGT Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global CGT Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global CGT Drugs Sales by Country (2027-2032)
  6. 7.4 Global CGT Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global CGT Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global CGT Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA CGT Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA CGT Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA CGT Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada CGT Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada CGT Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada CGT Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico CGT Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico CGT Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico CGT Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany CGT Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany CGT Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany CGT Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France CGT Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France CGT Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France CGT Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. CGT Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. CGT Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. CGT Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy CGT Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy CGT Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy CGT Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain CGT Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain CGT Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain CGT Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia CGT Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia CGT Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia CGT Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands CGT Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands CGT Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands CGT Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries CGT Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries CGT Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries CGT Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China CGT Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China CGT Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China CGT Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan CGT Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan CGT Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan CGT Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea CGT Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea CGT Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea CGT Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India CGT Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India CGT Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India CGT Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia CGT Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia CGT Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia CGT Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia CGT Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia CGT Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia CGT Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil CGT Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil CGT Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil CGT Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina CGT Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina CGT Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina CGT Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile CGT Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile CGT Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile CGT Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia CGT Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia CGT Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia CGT Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru CGT Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru CGT Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru CGT Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia CGT Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia CGT Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia CGT Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel CGT Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel CGT Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel CGT Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE CGT Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE CGT Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE CGT Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey CGT Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey CGT Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey CGT Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran CGT Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran CGT Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran CGT Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt CGT Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt CGT Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt CGT Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bluebird Bio
  2. 8.1.1 Bluebird Bio Company Information
  3. 8.1.2 Bluebird Bio Business Overview
  4. 8.1.3 Bluebird Bio CGT Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bluebird Bio CGT Drugs Product Portfolio
  6. 8.1.5 Bluebird Bio Recent Developments
  7. 8.2 Celgene Corporation
  8. 8.2.1 Celgene Corporation Company Information
  9. 8.2.2 Celgene Corporation Business Overview
  10. 8.2.3 Celgene Corporation CGT Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Celgene Corporation CGT Drugs Product Portfolio
  12. 8.2.5 Celgene Corporation Recent Developments
  13. 8.3 Juno Therapeutics
  14. 8.3.1 Juno Therapeutics Company Information
  15. 8.3.2 Juno Therapeutics Business Overview
  16. 8.3.3 Juno Therapeutics CGT Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Juno Therapeutics CGT Drugs Product Portfolio
  18. 8.3.5 Juno Therapeutics Recent Developments
  19. 8.4 Kite Pharma
  20. 8.4.1 Kite Pharma Company Information
  21. 8.4.2 Kite Pharma Business Overview
  22. 8.4.3 Kite Pharma CGT Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Kite Pharma CGT Drugs Product Portfolio
  24. 8.4.5 Kite Pharma Recent Developments
  25. 8.5 Orchard Therapeutics
  26. 8.5.1 Orchard Therapeutics Company Information
  27. 8.5.2 Orchard Therapeutics Business Overview
  28. 8.5.3 Orchard Therapeutics CGT Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Orchard Therapeutics CGT Drugs Product Portfolio
  30. 8.5.5 Orchard Therapeutics Recent Developments
  31. 8.6 Spark Therapeutics
  32. 8.6.1 Spark Therapeutics Company Information
  33. 8.6.2 Spark Therapeutics Business Overview
  34. 8.6.3 Spark Therapeutics CGT Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Spark Therapeutics CGT Drugs Product Portfolio
  36. 8.6.5 Spark Therapeutics Recent Developments
  37. 8.7 Amgen
  38. 8.7.1 Amgen Company Information
  39. 8.7.2 Amgen Business Overview
  40. 8.7.3 Amgen CGT Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Amgen CGT Drugs Product Portfolio
  42. 8.7.5 Amgen Recent Developments
  43. 8.8 Fosun Kite Biotechnology
  44. 8.8.1 Fosun Kite Biotechnology Company Information
  45. 8.8.2 Fosun Kite Biotechnology Business Overview
  46. 8.8.3 Fosun Kite Biotechnology CGT Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Fosun Kite Biotechnology CGT Drugs Product Portfolio
  48. 8.8.5 Fosun Kite Biotechnology Recent Developments
  49. 8.9 GSK
  50. 8.9.1 GSK Company Information
  51. 8.9.2 GSK Business Overview
  52. 8.9.3 GSK CGT Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 GSK CGT Drugs Product Portfolio
  54. 8.9.5 GSK Recent Developments
  55. 8.10 Novartis
  56. 8.10.1 Novartis Company Information
  57. 8.10.2 Novartis Business Overview
  58. 8.10.3 Novartis CGT Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Novartis CGT Drugs Product Portfolio
  60. 8.10.5 Novartis Recent Developments
  61. 8.11 SiBiono
  62. 8.11.1 SiBiono Company Information
  63. 8.11.2 SiBiono Business Overview
  64. 8.11.3 SiBiono CGT Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 SiBiono CGT Drugs Product Portfolio
  66. 8.11.5 SiBiono Recent Developments
  67. 8.12 Sunway Biotech
  68. 8.12.1 Sunway Biotech Company Information
  69. 8.12.2 Sunway Biotech Business Overview
  70. 8.12.3 Sunway Biotech CGT Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Sunway Biotech CGT Drugs Product Portfolio
  72. 8.12.5 Sunway Biotech Recent Developments
  73. 8.13 Janssen Biotech
  74. 8.13.1 Janssen Biotech Company Information
  75. 8.13.2 Janssen Biotech Business Overview
  76. 8.13.3 Janssen Biotech CGT Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Janssen Biotech CGT Drugs Product Portfolio
  78. 8.13.5 Janssen Biotech Recent Developments
  79. 8.14 Sequoia
  80. 8.14.1 Sequoia Company Information
  81. 8.14.2 Sequoia Business Overview
  82. 8.14.3 Sequoia CGT Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Sequoia CGT Drugs Product Portfolio
  84. 8.14.5 Sequoia Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 CGT Drugs Value Chain Analysis
  2. 9.1.1 CGT Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 CGT Drugs Sales Mode & Process
  6. 9.2 CGT Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 CGT Drugs Distributors
  9. 9.2.3 CGT Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst